Spurious correlation in estimation of the health production function: A note by Akkoyunlu, Sule et al.
  
 
 
Socioeconomic Institute 
Sozialökonomisches Institut 
 
 
 
 
 
Working Paper No. 0903 
 
Spurious correlation in estimation of the health 
production function:  
A note 
 
Sule Akkoyunlu, Frank R. Lichtenberg, Boriss Siliverstovs, Peter Zweifel 
 
February 2009  
 
 
Socioeconomic Institute 
University of Zurich 
 
Working Paper No. 0903 
 
Spurious correlation in estimation of the health production function: A note 
 
 
 
 
February 2009 
 
Author's address:  Sule Akkoyunlu 
  E-mail: sule.akkoyunlu@soi.uzh.ch 
 
  Frank R. Lichtenberg 
  E-mail: frank.lichtenberg@columbia.edu 
 
  Boriss Siliverstovs 
  E-mail: boriss.siliverstovs@kof.ethz.ch 
 
  Peter Zweifel 
  E-mail: pzweifel@soi.uzh.ch 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publisher  Sozialökonomisches Institut 
Bibliothek (Working Paper) 
Rämistrasse 71 
CH-8006 Zürich 
Phone: +41-44-634 21 37 
Fax: +41-44-634 49 82 
URL: www.soi.uzh.ch 
E-mail: soilib@soi.uzh.ch 
Spurious correlation in estimation of the health production function:  
A note 
 
Sule Akkoyunlu♥, Frank R. Lichtenberg♣, Boriss Siliverstovs♦ and Peter Zweifel♠  
 
November 2008 
 
Abstract 
 
 
In this paper, we address the issue of spurious correlation in the production of health in a 
systematic way. Spurious correlation entails the risk of linking health status to medical (and 
nonmedical) inputs when no links exist. This note first presents the bounds testing procedure 
as a method to detect and avoid spurious correlation. It then applies it to a recent contribution 
by Lichtenberg (2004), which relates longevity in the United States to pharmaceutical 
innovation and public health care expenditure.  The results of the bounds testing procedure 
show longevity to be linearly related to these two factors. Therefore, the estimates reported by 
Lichtenberg (2004) cannot be said to be result of spurious correlation, to the contrary, they 
very likely reflect an effective relationship, at least for the United States. 
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1. Introduction 
Although empirical research into the production of health can benefit greatly from time series 
data, there are only few examples [Katsouyanni et al. (1997), Woodruff et al. (1997), Samet et 
al. (2000), Shmueli (2003), and Lichtenberg (2004, 2006)]. However, in these studies the 
issue of spurious regression has never been addressed in a systematic way, in spite of its 
particular relevance to time series analysis. This failure is important because it entails the risk 
of linking health status to medical (and nonmedical) inputs when no links exist. It is even 
gaining in importance in view of evidence presented by Lichtenberg (2004) suggesting that 
recent increases in U.S. life expectancy are attributable to pharmaceutical innovation and 
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public health care expenditure (HCEP) rather than health care expenditure (HCE) in general 
and nonmedical determinants such as real GDP per capita which are found to be insignificant.   
 
In their pioneering analysis, Granger and Newbold (1974) showed that when the dependent 
and explanatory variables are integrated of order one [technically, I(1)], analysis of the 
relationship between these variables using the ordinary least squares is likely to be subject to 
spurious correlation. To exclude this possibility, one either has to prove that the variables in 
question are (trend-)stationary or that the I(1) variables are cointegrated. Alternatively, one 
has to use a method that works equally well irrespective of the underlying integration order of 
the variables. One such method is the bounds testing procedure suggested by Pesaran, Shin, 
and Smith (2001). We apply it to the Lichtenberg (2004) data in order to sort out whether the 
results reported therein are due to spurious correlation or reflect a genuine relationship 
between the variables in question. 
 
2. Method  
In order to resolve the spurious correlation problem, the bounds testing procedure developed 
by Pesaran et al. (2001) will be presented in the following. This choice can be justified based 
on the following considerations. First, the bounds testing approach has broad applicability 
since the regressors can be I(1), I(0), or mutually cointegrated. This is a great advantage since 
the unit root tests regarding the order of integration of the relevant variables yield 
inconclusive results (as discussed in Lichtenberg, 2004). Second, the procedure is based on 
the unrestricted error correction model, which permits joint estimation of long and short-run 
effects. As pointed out in Banerjee et al. (1993, 1998), joint estimation has better statistical 
properties than the two-step Engle-Granger procedure that pushes the short-run dynamics into 
the error term. Third, as discussed in Narayan (2005), the bounds testing procedure performs 
rather well in small samples like the one employed in Lichtenberg (2004).  In small samples, 
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application of the more popular Full Information Maximum Likelihood method (Johansen, 
1995) is problematic. 
 
To implement the bounds testing procedure in the present context, one assumes that life 
expectancy (LE), new molecular entities (NME, a measure of pharmaceutical innovation), and 
public health care expenditures per capita (HCEP) are related according to a vector 
autoregressive (VAR) model. Dropping real GDP and health care expenditures in general that 
were found insignificant by Lichtenberg (2004) and also by us,  the VAR model that can be 
reduced to the following conditional error correction model (ECM), 
1
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Here, p is the lag length of the underlying VAR model. The lagged values of LE, NME and 
HCEP (are in logs) form a long-run relationship in levels. The deterministic terms such as a 
constant, a linear trend, and dummy variables are denoted by DTt. The short-run dynamics is 
captured by means of lagged values of ΔLEt and current and lagged values of ΔNMEt  and 
ΔHCEPt. The data span the time period from 1960 to 2001. The conditional long-run 
elasticities of life expectancy with respect to MNE and HCEP are given by –θ1/ θ0 and –θ2/ θ0, 
respectively (Banerjee et al., 1998). 
 
The bounds testing procedure uses the conventional F test for testing the null hypothesis : 
θ
0H
1=θ2=0. Note that this statistic has a non-standard distribution which depends upon (i) the 
order of integration of the regressors; (ii) the number of regressors; (iii) the set of 
deterministic terms included in the model; and (iv) sample size.  Pesaran et al. (2001) provide 
the set of asymptotic critical values, generated from 1,000 bootstraps. However, given a small 
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sample size (41 observations in the present case), these values are likely to be inappropriate. 
Therefore, the critical values reported in Narayan (1995) for small sample sizes are used in 
the following. 
 
There are two sets of critical values. The first set gives the lower bound, applicable when all 
regressors are I(0). The second gives the upper bound, applicable when all regressors are I(1). 
If the calculated F statistic falls below the lower bound, the null hypothesis of no relationship 
in levels cannot be rejected. Conversely, if the F statistic exceeds the upper bound, the null 
hypothesis of a level relationship can be accepted. Both rules hold irrespective of the order of 
integration of the regressors. Finally, if the F statistic falls within the critical bounds, the order 
of integration of the variables must be established in order to obtain conclusive inference. 
 
3. Test results 
Table 1 presents the results of the lag order p selection procedure for equation (1). The 
information criteria (Akaike, AIC and Schwarz, SIC) as well as the Langrange Multiplier 
statistic testing for remaining autocorrelation of order 1 and up to 4 in regression residuals are 
reported. As a robustness check, equation (1) is estimated without and with a linear trend. 
_______________ 
Table 1 about here 
 
When no deterministic trend is included, the AIC selects p=2 whereas the SIC selects p=1. In 
both cases, there is no evidence of remaining autocorrelation in the regression residuals. 
Adding a linear deterministic term does not change these conclusions. Given the evidence of 
no residual autocorrelation regardless of the value of p and a rather small number of 
observations, the parsimonious model with p=1 is preferred. Next, it seems that inclusion of a 
linear deterministic trend is not supported either by AIC or SIC, since both statistics take on a 
 4
higher value (indicating better fit) without a linear trend. Therefore, the model with p=1 and 
without a linear trend in Table 1 will be used for the bounds testing procedure. Nevertheless, 
the results with a trend included will also be reported to provide some sensitivity analysis.  
 
From the five cases distinguished by Pesaran et al. (2001), the preliminary results reported 
above calls for retaining the following three,  
Case III: unrestricted constant and no trend;  
Case IV: unrestricted constant and restricted trend;  
Case V: unrestricted constant and unrestricted trend.  
The corresponding F test statistics are denoted as FIII, FIV, and FV in Table 2. They exceed the 
critical upper bound (1 percent significance level) in all cases except for FV, which exceeds 
the critical upper bound at the 5 percent significance level for p=2. This finding indicates that 
the null hypothesis of no relationship in levels can be rejected. Thus, longevity, the number of 
new molecular entities, and public per capita health expenditure are linearly related. This 
finding is robust both to lag length and the inclusion of a deterministic trend.  
_______________ 
Table 2 about here 
 
Next, one can capitalize on the existence of this relationship for the modelling of the health 
production function. The objective is to find the most parsimonious model passing the 
standard diagnostic tests.  The implied values of the long-run impact coefficients of that 
model can then be compared with those reported by Lichtenberg (2004). The equation 
obtained reads (standard errors in parentheses, error probabilities in brackets),  
-1 -1
-1
 =  0.770 + 0.00496*  - 0.196* + 0.00802*
            (0.140)   (0.0011)                (0.037)              (0.0016)      
         + 0.00849*  - 0.00559* 93
            (0.00
t t t
t t
LE NME LLE NME
HCEP D
Δ Δ
19)                         (0.0022)    
t
                              (2)      
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R2 = 0.566, F(5,35) =  9.129 [0.000], T =  41 
AR 1-2 test: F(2,33)  =  1.651 [0.207]   
ARCH 1-1 test:     F(1,33)   = 0.140 [0.710]   
Normality test: )2(2χ    = 0.241 [0.886]   
Heteroskedasticity test: F(9,25)    = 1.218 [0.329]   
Heteroskedasticity-X test:     F(15,19)  = 1.135 [0.392]   
RESET test:                           F(1,34)   = 0.683 [0.415]   
 
All coefficients are estimated with a high degree of precision. The model passes all standard 
specification tests, including tests of no residual autocorrelation, of no residual ARCH effects, 
of no residual heteroskedasticity, of residual normality, and of no functional form 
misspecification. These encouraging results are also supported by the close match between 
actual and the fitted values displayed in the top panel of Figure 1.  The estimated regression 
residuals show no sign of misspecification (middle panel).1 Finally, the autocorrelation 
function (bottom panel) takes on rather small values that moreover change signs for lags 
ranging from 1 to 5 years.  
 
Finally, the results of the Chow tests for recursive stability (Chow, 1960) are shown in Figure 
2.  The values of the 1-step, breakpoint, and forecast Chow test statistics are compared to their 
respective 5% critical values (Doornik and Hendry, 2001).  None of the tests show any sign of 
model instability. 
 
                                                 
1 In Equation (2), D93 denotes a dummy that is equal to one in 1993 and zero otherwise. The dummy in 1993 accounts for a decrease in life-
expectancy in that year that cannot be explained by developments neither in pharmaceutical innovation nor in public health care 
expenditures. According to Kranczer (1994), “In 1993, a decrease in life expectation was primarily brought about by the considerable rise in 
the absolute number of deaths and the corresponding increase in mortality rates. Indications are that mortality increased from all major forms 
of death as well as from AIDS. It is estimated that there were 2,260,000 deaths in 1993 compared with the provisional count of 2,177,000 in 
1992 and the final figure of 2,169,518 in 1991.” 
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According to equation (2), the long-run elasticities of life expectancy with respect to 
pharmaceutical innovation and public health expenditure are 0.0408 and 0.0432, respectively. 
These values are close to those reported in Lichtenberg (2004, Table 3), i.e. 0.0390 and 
0.0434. In sum, the estimates reported by Lichtenberg (2004) cannot be said to result from 
spurious correlation; to the contrary, they very likely reflect an effective relationship between 
life expectancy on the one hand and, pharmaceutical innovation and public health care 
expenditure on the other in the United States.  
 
4. Concluding remarks 
As already noted by Gerdtham and Jönsson (2000), health economists until recently have 
been paying rather little attention to the fact that some of their data are of the time series type. 
However, there are modern econometric techniques for detecting the existence of a 
relationship between variables that can be integrated either of order one or zero, or mutually 
cointegrated. Applying these techniques to the paper by Lichtenberg (2004), this note finds 
that the null hypothesis of no relationship between life expectancy, pharmaceutical 
innovation, and public health care expenditure in the United States can be rejected. However, 
there are other recent works that might be subjected to a similar scrutiny. For example, 
Zweifel et al. (2005) employ panel data for revisiting the so-called Sisyphus syndrome 
(Zweifel and Ferrari, 2002), which involves a production function (HCE resulting in more 
elderly survivors) and a HCE function (where elderly survivors exert public pressure for more 
HCE). Other panel data applications that investigate the relation between life expectancy and 
health care spending include Crémieux et al. (1999), and Or (2001). More specifically, the 
findings by Peltzman (1987), Lichtenberg (1996), Moore and Newman (1993), Soumerai et 
al. (1994), and Crémieux et al. (2005), that pharmaceutical consumption contribute life 
expectancy could be checked using the testing procedures described in this note.   
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 Table 1 Lag order selection 
          
 Without deterministic trends  With deterministic trends 
p AIC SIC AR(1) AR(4)  AIC SIC AR(1) AR(4) 
          
1 -9.377 -9.078 0.158 0.448  -9.340 -8.999 0.190 0.480 
2 -9.382 -8.956 0.357 0.533  -9.344 -8.875 0.370 0.540 
3 -9.278 -8.723 0.818 0.469  -9.230 -8.633 0.792 0.459 
          
Notes: p is the lag order of the underlying VAR model for the conditional ECM of 
equation (1). Bold entries indicate the preferred lag order. 
AIC and SIC are the Akaike and Scwarz Information Criteria, respectively. 
AR(1) and AR(4) are the LM test statistics for testing for residual autocorrelation of 
orders up to 1 and 4, respectively. 
 
 
Table 2 F-test statistics for testing the existence of a levels relationship 
    
p FIII FIV FV
    
1 10.437*** 10.556*** 10.385*** 
2 7.607*** 7.839*** 7.565** 
    
Notes:  FIII, FIV, and FV are the F-test statistics that correspond to the three cases 
mentioned in Pesaran et al. (2001): Case III – an unrestricted constant and no linear 
deterministic trend; Case IV – unrestricted constant and restricted linear deterministic
trend; Case V –  unrestricted constant and unrestricted linear deterministic trend.  
Symbols ‘***’ and ‘**’ indicate that the F-statistic exceeds the upper bound 
corresponding to the 1% and 5% significance levels, respectively, as reported in
Narayan (2005) for T = 40. 
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Figure 1: Actual and fitted values (the upper panel); Regression residuals (the middle panel); 
Autocorrelation function of regression residuals (bottom panel). 
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Figure 2: Recursive stability 1-step, breakpoint, and forecast Chow test statistics scaled by 
their respective 5% critical values. 
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